YTEN
NASDAQYield10 Bioscience Inc.
IPO2006
Latest news
25 items- SECYield10 Bioscience Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Costs Associated with Exit or Disposal Activities, Leadership Update, Financial Statements and Exhibits8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
- SECYield10 Bioscience Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
- SECYield10 Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
- PRYield10 Bioscience Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key ProposalsSpecial Meeting Adjourned to Thursday, November 21, 2024 WOBURN, MA / ACCESSWIRE / November 8, 2024 / Yield10 Bioscience, Inc. (OTCQB:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that its Special Meeting of Stockholders (the "Special Meeting"), scheduled to be held at 11:00 a.m., Eastern Time, on November 8, 2024, was convened and adjourned, without any business being conducted, due to lack of sufficient votes in favor of the key proposals related to the Asset Sale to Nuseed and the Dissolution proposal.To pass the proposals, more than 50% of the shares of common stock outstanding and entitled to vote as of the close of business on October 3, 2024
- SECYield10 Bioscience Inc. filed SEC Form 8-K: Leadership Update8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
- SECSEC Form DEFM14A filed by Yield10 Bioscience Inc.DEFM14A - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
- SECYield10 Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
- SECSEC Form PREM14A filed by Yield10 Bioscience Inc.PREM14A - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
- SECYield10 Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
- INSIDERVP Research and CSO Snell Kristi covered exercise/tax liability with 877 shares, decreasing direct ownership by 11% to 6,999 units (SEC Form 4)4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)
- INSIDERVP Planning and Communications Brum Lynne H covered exercise/tax liability with 731 shares, decreasing direct ownership by 11% to 5,867 units (SEC Form 4)4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)
- INSIDERVP Finance and CAO Haaser Charles B covered exercise/tax liability with 731 shares, decreasing direct ownership by 11% to 5,949 units (SEC Form 4)4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)
- INSIDERPresident and CEO Peoples Oliver P covered exercise/tax liability with 1,463 shares, decreasing direct ownership by 10% to 12,634 units (SEC Form 4)4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)
- PRYield10 Bioscience Announces Second Quarter 2024 Financial ResultsWOBURN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the second quarter ended June 30, 2024. "We continue to work closely with the Nufarm team to finalize the asset purchase agreement announced in July," said Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10. "We believe that the transition of our Omega-3 Camelina program to Nufarm is in the best interest of our shareholders, business partners, and employees. Receipt of the initial $3 million payment and progress toward earning an additional $2 million milestone payment is enabling
- SECSEC Form 10-Q filed by Yield10 Bioscience Inc.10-Q - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
- SECSEC Form 424B3 filed by Yield10 Bioscience Inc.424B3 - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
- SECSEC Form EFFECT filed by Yield10 Bioscience Inc.EFFECT - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
- SECYield10 Bioscience Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
- PRYield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of AssetsWEST SACRAMENTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company has signed a Memorandum of Understanding ("MOU") and License Agreement with Nuseed Nutritional US Inc. (the seed technologies platform of Nufarm Limited (ASX:NUF)), granting Nufarm a commercial license to certain Omega-3 intellectual property assets, materials and know-how for producing oil in Camelina. Nufarm and Yield10 have additionally agreed to immediately negotiate exclusively with each other for the sale of Yield10's remaining assets to Nufarm. The asset sale will require an affirmative vote
- SECYield10 Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
- PRYield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets- Nufarm to pay up to USD $5 million in consideration for the license-The parties will negotiate the sale of essentially all of Yield10's assets to Nufarm WOBURN, Mass. and WEST SACRAMENTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company has signed a Memorandum of Understanding ("MOU") and License Agreement with Nuseed Nutritional US Inc. (the seed technologies platform of Nufarm Limited (ASX:NUF)), granting Nufarm a commercial license to certain Omega-3 intellectual property assets, materials and know-how for producing oil in Camelina. Under the License Agreeme
- PRRothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in CamelinaWOBURN, Mass. and HARPENDEN, United Kingdom, June 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that U.K.-based Rothamsted Research Limited ("Rothamsted") has granted to the Company an exclusive global, commercial license to advanced technology for producing sustainable omega-3 products in Camelina sativa ("Camelina"). Yield10 is executing a plan to use engineered Camelina to commercially produce omega-3 oil and meal products targeting the aquafeed, petfood, and nutritional markets for omega-3 fatty acids. In consideration for the commercial license, Yield10 is expected to pay certain licen
- SECYield10 Bioscience Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
- SECYield10 Bioscience Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
- SECSEC Form S-1/A filed by Yield10 Bioscience Inc. (Amendment)S-1/A - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)
YTEN FAQ
5 questionsWhat does Yield10 Bioscience Inc. do?
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada. The company, through its Trait Factory, is involved in developing oilseed Camelina to produce proprietary products; and high value seed traits for the agriculture and food industries. Yield10 Bioscience, Inc. has license agreements with GDM Seeds; J. R. Simplot; Forage Genetics International, LLC; and Bayer AG. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January...Where does YTEN stock trade?
Yield10 Bioscience Inc. (YTEN) is listed on NASDAQ.When did Yield10 Bioscience Inc. go public?
Yield10 Bioscience Inc. (YTEN) completed its IPO in 2006.What are analysts saying about YTEN?
Yield10 Bioscience Inc. has had 2 recent analyst actions on file. The most recent action was from Lake Street: Hold on 2024-02-08. Recent price targets cluster around $900.00.How can I track YTEN on Quantisnow?
Quantisnow aggregates Yield10 Bioscience Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow YTEN to receive live email and push alerts on every new disclosure.